Top Healthcare Stocks:
Healthcare shares are mixed in pre-market trade. Astex
) is up 9.9% at $6.02 as it reports topline results from the
ongoing phase 2 of SGI-110 in patients with AML and MDS. The Phase
2 study is a randomized study of SGI-110 given either as 60 or 90
mg/m2 daily for 5 days in a 28-day course.
The primary endpoint is overall remission rate. There were 8
remissions in relapsed/refractory AML and 9 remissions in
treatment-naive elderly AML for an overall complete remission rate
of 17/67 or 25%.
And, EDAP (
) says Q2 sales were EUR 4.5 million, or USD 5.9 million, below the
Thomson Reuters estimate for USD 7.8 million.
Loss was EUR 0.01 per diluted share, with items. Estimates,
usually less items, were for USD $0.05 loss. EDAP shares are down
2% at $2.56 in pre-market trade.
Finally, Sincere Pharmaceutical Group (
) said its parent company Sincere Holding Limited will buy its
shares for $4.83 per ordinary share and $9.66 per American
depository share. SCR shares are flat at $9.36 pre-market.
Copyright (C) 2013 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.